Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.
In this double-blind, single-dose phase I study, the safety and tolerance of cefepime were assessed in 24 healthy male subjects, with ceftazidime as the control drug. Four subjects in each of the six dose groups (62.5, 125, 250, 500, 1,000, or 2,000 mg as a 30-min intravenous infusion) received each antibiotic, according to a crossover design, with a 2-day washout period between treatments. Blood and urine samples were obtained to characterize the pharmacokinetics of cefepime. Plasma and urine samples were assayed for intact cefepime. Samples containing ceftazidime were discarded. The adverse effects observed in the study were mild and infrequent, with prompt recovery from adverse experiences and abnormal laboratory values. The cefepime pharmacokinetic parameters for the therapeutically significant doses of 250 to 2,000 mg appeared to be proportional to dose and similar to literature values for ceftazidime. The elimination half-life of about 2 h was independent of the dose. Urinary recovery of intact cefepime was invariant with respect to dose; an overall mean value of 82% of dose was obtained for the four highest levels. Mean renal clearance was 105 ml/min and suggestive of glomerular filtration as the primary excretion mechanism. In normal humans, the safety and pharmacokinetic profiles of cefepime are very similar to those of ceftazidime.
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Syracuse, New York 13221-4755.
R H
RH
Barbhaiya
S T
ST
Forgue
C R
CR
Gleason
C A
CA
Knupp
K A
KA
Pittman
D J
DJ
Weidler
R R
RR
Martin
D000328:Adult; D000077723:Cefepime; D002442:Ceftazidime / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D015394:Molecular Structure; D012016:Reference Values
D002511:Cephalosporins; D000077723:Cefepime; D002442:Ceftazidime